Cubist Pharmaceuticals, Inc. Enrolls First Patient in Phase 3 Efficacy Studies Evaluating Bevenopran for the Treatment of Opioid-Induced Constipation

Published: Jul 19, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the initiation of Phase 3 efficacy studies of bevenopran (previously known as CB-5945) in patients with chronic non-cancer pain and opioid-induced constipation (OIC). The Phase 3 program, ASCENT, includes three identically-designed studies that will enroll approximately 600 patients each (1,800 total) designed to evaluate the efficacy and safety of bevenopran (0.25 mg orally twice daily) vs. placebo. The ASCENT program also includes a 1,400-patient one-year, placebo-controlled safety study which was initiated in October 2012.

Help employers find you! Check out all the jobs and post your resume.

Back to news